BRAF V600E Clinical Trials

13 recruitingLast updated: June 18, 2026

There are 13 actively recruiting braf v600e clinical trials across 10 countries. Studies span Phase 2, Early Phase 1, Not Applicable, Phase 1. Top locations include Kyoto, Japan, Paris, France, Durham, North Carolina, United States. Updated daily from ClinicalTrials.gov.


BRAF V600E Trials at a Glance

13 actively recruiting trials for braf v600e are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 2 with 6 trials, with the heaviest enrollment activity in Kyoto, Paris, and Durham. Lead sponsors running braf v600e studies include Novartis Pharmaceuticals, Institut de Recherches Internationales Servier, and Grupo Español Multidisciplinar de Melanoma.

Browse braf v600e trials by phase

Treatments under study

About BRAF V600E Clinical Trials

Looking for clinical trials for BRAF V600E? There are currently 4 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new BRAF V600E trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about BRAF V600E clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting
Phase 1Phase 2

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Colorectal, CancerColorectal CarcinomaNon-small Cell Lung Cancer+29 more
Institut de Recherches Internationales Servier554 enrolled27 locationsNCT05786924
Recruiting

Special Drug Use-results Surveillance of Tafinlar/Mekinist

BRAF V600E Mutation-positive Unresectable Advanced or Recurrent Solid Tumor
Novartis Pharmaceuticals110 enrolled70 locationsNCT06262919
Recruiting

Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer

Metastatic Colorectal CancerBRAF V600E Mutation
Swiss Cancer Institute30 enrolled12 locationsNCT07617610
Recruiting
Phase 2

Hydroxychloroquine in Combination With Encorafenib and Cetuximab or Panitumumab in the Treatment of Metastatic BRAF-mutated Colorectal Cancer Refractory

Colorectal, CancerColorectal Cancer Stage IVStage IV Colorectal Cancer Positive for BRAF V600E Mutation
Northwestern University43 enrolled8 locationsNCT05576896
Recruiting
Early Phase 1

A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

BRAF V600E Mutation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins24 enrolled1 locationNCT06610682
Recruiting
Phase 2

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Colorectal, CancerBRAF V600ESintilimab+4 more
Tianjin Medical University Cancer Institute and Hospital49 enrolled4 locationsNCT07506109
Recruiting

Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors

Rare Unresectable or Metastatic BRAF V600E Mutation-positive Solid Tumors
Novartis Pharmaceuticals40 enrolled8 locationsNCT05868629
Recruiting

Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy

Non-small Cell Lung CancerALK Gene MutationEGFR Gene Mutation+3 more
University of Colorado, Denver100 enrolled1 locationNCT03042221
Recruiting
Not Applicable

A Clinical-biological Prospective Cohort of Patients With BRAFV600E-mutated Metastatic Colorectal Cancer

Metastatic Colorectal CancerBRAF V600E Mutation Positive
UNICANCER400 enrolled45 locationsNCT05639413
Recruiting
Phase 2

Encorafenib and biNimetinib Followed by CEmiplimab and FiAnLimab in Patients With BRAF Mutant melanOma and Symptomatic Brain Metastases

Melanoma BRAF V600E/K MutatedMelanoma and Brain Metastases
Grupo Español Multidisciplinar de Melanoma33 enrolled18 locationsNCT06887088
Recruiting
Phase 2

Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer

Colorectal, CancerBRAF V600E Mutation Positive
Federation Francophone de Cancerologie Digestive30 enrolled1 locationNCT05706779
Recruiting
Phase 2

Clinical Study of Neoadjuvant Targeted Therapy for Ameloblastoma

BRAF V600E Mutation PositiveAmeloblastoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University12 enrolled1 locationNCT06653517
Recruiting

Preoperative Hemogram Parameters and BRAF Molecular Test Detected by Bethesda 3 Cytology.

BRAF V600EThyroid NoduleBlood Platelet Disorder+1 more
Saglik Bilimleri Universitesi120 enrolled1 locationNCT06539702